Aadi Bioscience discloses compensation for interim CEO Scott Giacobello: quarterly bonus, option grant

Whitehawk Therapeutics, Inc.

Scott Giacobello appointed Interim CEO and President effective March 15, 2023; remains CFO.
Quarterly bonus of $43,000 (prorated) approved for interim role.
Eligible for annual cash bonus at 90% of base salary based on performance objectives.
Received stock option for 100,000 shares vesting over 4 years with standard schedule.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Scott Giacobello

Interim Chief Executive Officer and President

WHWK · Whitehawk Therapeutics, Inc.

Effective: 2023-03-15
Filed: March 28, 2023, 7:59 PM ET

appointed Scott Giacobello as the Company’s Interim Chief Executive Officer and President, effective March 15, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Scott Giacobello was appointed as Interim Chief Executive Officer and President at Whitehawk Therapeutics, Inc..

Action: appointed
Role: Interim Chief Executive Officer and President

Exact text from the filing

appointed Scott Giacobello as the Company’s Interim Chief Executive Officer and President, effective March 15, 2023.

View on SEC.gov

Whitehawk Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-082149

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.